Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii.

Antimicrobial Agents and Chemotherapy
Moti ChapagainShashikant Srivastava

Abstract

The combination of isoniazid, rifampin, and ethambutol is recommended by the American Thoracic Society (ATS) for treatment of pulmonary Mycobacterium kansasii, while the British Thoracic Society (BTS) recommends clarithromycin, rifampin and ethambutol. Unfortunately, therapy duration for both regimens lasts for years. In this study, we administered tedizolid, minocycline, clarithromycin, and rifapentine as monotherapy as well as novel combinations in the intracellular hollow-fiber model system of M. kansasii (HFS-Mkn) in a 28-day study. The ATS and BTS regimens were used as comparators. Repetitive sampling was used to validate the intended intrapulmonary pharmacokinetics of each drug and to monitor changes in M. kansasii burden. As monotherapy, tedizolid at an observed area under the concentration-time curve from 0 to 24 h (AUC0-24)/MIC of 5.85 and minocycline at an AUC0-24/MIC of 5.77 failed to kill the bacteria below day 0 (stasis), clarithromycin at an AUC0-24/MIC of 2.4 held the bacterial burden at stasis, but rifapentine at an AUC0-24/MIC of 140 killed 2 log10 CFU/ml below stasis. The BTS regimen kill slope was -0.083 ± 0.035 CFU/ml/day, which was significantly superior to the ATS regimen slope of -0.038 ± 0.038 CFU/ml/day...Continue Reading

References

May 1, 1992·Journal of Clinical Microbiology·I NachamkinS Barbagallo
Dec 1, 1982·The Journal of Infectious Diseases·R C Good, D E Snider
Sep 15, 2005·Journal of Medical Microbiology·Maria Alice da Silva TellesLee W Riley
Feb 6, 2007·American Journal of Respiratory and Critical Care Medicine·David E GriffithUNKNOWN Infectious Disease Society of America
Aug 13, 2011·Current Pharmaceutical Design·Shashikant Srivastava, Tawanda Gumbo
Oct 10, 2014·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·S K BrodeT K Marras
Mar 16, 2016·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Jason E StoutWing Wai Yew
Sep 20, 2017·The Journal of Antimicrobial Chemotherapy·Devyani DeshpandeTawanda Gumbo
Sep 20, 2017·The Journal of Antimicrobial Chemotherapy·Devyani DeshpandeTawanda Gumbo
May 31, 2018·Antimicrobial Agents and Chemotherapy·Shashikant Srivastava, Tawanda Gumbo
Nov 30, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Devyani DeshpandeTawanda Gumbo
Nov 30, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Shashikant SrivastavaTawanda Gumbo
Mar 2, 2019·The Journal of Antimicrobial Chemotherapy·Devyani DeshpandeTawanda Gumbo

❮ Previous
Next ❯

Citations

Mar 23, 2021·Clinical Pharmacokinetics·Jan-Willem AlffenaarCharles A Peloquin
Feb 10, 2021·Antimicrobial Agents and Chemotherapy·Shashikant SrivastavaTawanda Gumbo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Related Papers

Antimicrobial Agents and Chemotherapy
Shashikant Srivastava, Tawanda Gumbo
Frontiers in Microbiology
Michelle S DeStefanoMichael H Cynamon
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
David E GriffithR J Wallace
Thorax
H Israel, J E Gottlieb
© 2021 Meta ULC. All rights reserved